Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple heart rate drug prevent Surgery-Related heart attacks?

NCT ID NCT07168421

Disease control Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether the drug landiolol can safely keep heart rate below 90 beats per minute during major surgery in 114 patients with heart risks. The goal is to see if this approach is feasible and might reduce heart injury after surgery. Participants receive the drug through an IV during and after their operation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Landiolol (a short-acting beta-blocker given intravenously)
What this could lead to
If successful, this could show that controlling heart rate during surgery reduces heart damage in at-risk patients, paving the way for a larger trial.
What could go wrong
This is a small feasibility trial, not designed to prove effectiveness. The drug may cause low blood pressure or require additional medications. Results may not apply to all surgery types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 114 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing elective non-cardiac surgery defined as intermediate or high-risk by the 2022 european society of cardiology (ESC) guidelines * surgery performed under general anesthesia; * expected length of hospital stay ≥ 24 hours; * age ≥ 45 years; * at least two of the following risk factors: * age ≥ 75 years * arterial hypertension; * ischemic heart disease (history of myocardial infarction or positive exercise test, current complaint of chest pain considered to be secondary to myocardial ischemia, use of nitrates, pathological Q waves, prior coronary revascularization); * history of congestive heart failure; * history of cerebrovascular disease; * peripheral artery disease; * diabetes mellitus; * GFR ≤ 59 ml/min pro 1.73 m2; * pre-operative NTproBNP \> 200 pg/ml; * excessive sympathetic outflow as proven by exercise testing: * impaired heart rate recovery (≤ 12 bpm within 1 minute after cessation of exercise); OR * exaggerated heart rate response (≥ 12 bpm after 3 minutes of unloaded pedalling); Exclusion Criteria: * unable to consent or follow study procedures; * absolute contraindications for exercise testing; * pregnancy or intention to become pregnant; * active cardiac conditions (such as unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease); * urgent / emergency surgery; * already on β-blocker (within the last 30 days prior to recruitment); * contraindication for β-blocker therapy (bradycardia (HR \< 55 bpm), hypotension (systolic blood pressure \< 100 mmHg), severe peripheral vascular disease, severe asthma, allergy, higher-degree atrioventricular block); * severe preoperative anaemia (haemoglobin \< 100 g/L) unless there is a plan set up and followed for correction prior to surgery; * planned intermediate care or intensive care admission; * prior enrolment in this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

primary dysautonomia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autonomic dysfunction Beta-blocker Cardiovascular (CV) risk Major surgery Myocardial injury after non-cardiac surgery Perioperative myocardial injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bern University Hospital, Freiburgstrasse

    RECRUITING

    Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.